Saturday February 22, 2020 07:13

NORDISK Press Releases

Novo Nordisk and Noom to partner around digital health solutions to help people with obesity lose Heathcare—02 Oct 19

Novo Nordisk, a global healthcare company, and Noom, a leading behaviour change company, today announced a collaboration on digital health solutions focusing on weight management and education, with the aim of improving the lives of people living with

Oral semaglutide improves glycaemic control in people with type 2 diabetes across baseline blood Heathcare—18 Sep 19

Novo Nordisk today announced findings from an exploratory analysis of the PIONEER trial programme, showing oral semaglutide (3, 7 and 14 mg) improved glycaemic control in people with type 2 diabetes across baseline HbA1c levels. Greater reductions in

Novo Nordisk focuses on relationship marketing while working to strengthen the brand image as a Events—30 Jul 19

Novo Nordisk Pharma (Thailand), a global healthcare company with 90 years of innovation and leadership in diabetes care, is organizing Obesity Symposium "Rethink Obesity : Obesity as a disease ?" which chaired by the distinguished guest - His Excellency

Novo Nordisk (Thailand) is hosting a press conference for the topic of Rethink Heathcare—19 Jul 19

Mr. John Dawber, Vice President and General Manager at Novo Nordisk (Thailand) is hosting a press conference for the topic of "Rethink Obesity". The event will be chaired by His Excellency Mr. Uffe Wolffhechel, Ambassador of Denmark to Thailand, and will

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established Heathcare—12 Jun 19

Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The

Ozempic(R) Superior in Lowering Blood Sugar and Weight Vs Placebo, Both in Combination with SGLT-2 Heathcare—05 Mar 19

Novo Nordisk today announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology. The objective of this 30 week trial was to assess the efficacy and safety of Ozempic(R) (semaglutide) 1.0 mg when added to

ฟูจิตะ คันโกะ Nordisk Village Goto Islands เปิดให้สำรองห้องพักแล้ววันนี้ ทั่วไป—23 Jul 18

"Nordisk Village Goto Islands"ที่พักกลางแจ้งสไตล์แคมป์ปิ้ง บริหารโดยบริษัทฟูจิตะคันโกะ อิงค์ (FUJITA KANKO INC.)บริษัทชั้นนำด้านการโรงแรมจากประเทศญี่ปุ่น มีกำหนดเปิดให้บริการอย่างเป็นทางการวันที่ 27 กันยายน 2018 ที่เกาะโกโตะ

Tessa Therapeutics ประกาศสมาชิกใหม่ของคณะกรรมการ พร้อมเพิ่มยอดระดมทุนครั้งล่าสุด สุขภาพ—17 Apr 18

- โกรัน อันโด อดีตประธานกรรมการบริษัท Novo Nordisk A/S เตรียมเข้าร่วมในคณะกรรมการบริหารของ Tessa - ยอดระดมทุนครั้งล่าสุดเพิ่มขึ้นถึง 50 ล้านดอลลาร์สหรัฐ เนื่องจากมีผู้สนใจเป็นจำนวนมากซึ่งส่งผลให้ยอดรวมทั้งหมดของการระดมทุนในครั้งนี้แตะ 130

ฟูจิตะคันโกะเปิดตัว Nordisk Village ครั้งแรกที่หมู่เกาะโกโตะ ประเทศญี่ปุ่น ไลฟ์สไตล์—05 Apr 18

บริษัทฟูจิตะคันโกะ อิงค์ (FUJITA KANKO INC.) บริษัทชั้นนำด้านการโรงแรมจากประเทศญี่ปุ่นประกาศเปิดตัว "Nordisk Village Goto Islands" ที่พักกลางแจ้งสไตล์แค้มปิ้งใหม่ในเดือนสิงหาคมนี้ เป็นโครงการร่วมกันกับ Nordisk Japan

Photo Release: The Royal Danish Embassy and Novo Nordisk Pharma (Thailand) Co., Ltd launch the Heathcare—14 Nov 17

On the 5th November 2017, right after the WDD event at the Vachirabenjatas Park (Suan Rot Fai Park) . Mr.Uffe Wolffhechel, the ambassador of the Royal Danish Embassy, Thailand (right) together with Mr.Mihai Irimescu, General Manager of Novo Nordisk

Photo Release: The Royal Danish Embassy and Novo Nordisk join together to support the World Heathcare—18 Oct 17

Recently, Mr.Uffe Wolffhechel, Ambassador of the Royal Danish Embassy, Thailand (right) together with Mr.Mihai Irimescu, General Manager of Novo Nordisk Pharma (Thailand) Co., Ltd (left) gave a special press interview on the 2017 World Diabetes Day event

IDF and Novo Nordisk Launch First-ever Global Survey on Cardiovascular Disease Awareness among Heathcare—29 Sep 17

- Taking Diabetes to Heart is a global online survey for people with type 2 diabetes to gain important insights about their awareness of cardiovascular disease (CVD) - Globally, CVD is the most common cause of death in people with type 2 diabetes[1] -

Tresiba(R) Trial Shows that People with Type 2 Diabetes who Avoid Severe Hypoglycaemia have a Heathcare—15 Sep 17

Novo Nordisk today announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycaemia (low blood sugar levels) are at greater risk of death. The risk was four-fold

Novo Nordisk to Present 35 Abstracts at the International Society on Thrombosis and Haemostasis Heathcare—03 Jul 17

Novo Nordisk announced today that data from 35 abstracts will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) congress from 8-13 July, in Germany. This data will be featured across posters, abstracts and oral

Tresiba(R) Demonstrated No Increased Risk Of Major Cardiovascular Events and Significant Reduction Heathcare—13 Jun 17

Novo Nordisk today announced the primary results from DEVOTE - the first randomised, double-blind, treat-to-target, event-driven trial comparing two basal insulins, Tresiba(R) (insulin degludec injection 100 U/mL) and insulin glargine U100, in adults

Fiasp(R)Black Triangle Drug, a new, ultra-fast acting mealtime insulin is available for the Heathcare—27 Mar 17

Today, Novo Nordisk announced that Fiasp(R), a new, fast-acting mealtime insulin for the treatment of diabetes in adults, has been launched in Canada, following the recent marketing authorisation from Health Canada on 6 January 2017. Fiasp(R) is insulin

NovoSeven(R) Resolved 96.5% of Bleeds When Initiated Within One Hour After Bleed Onset in People Heathcare—06 Dec 16

Novo Nordisk today announced that NovoSeven(R) (rFVIIa), a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds when initiated within one hour after onset of bleeding, demonstrating efficacy of early treatment in

Xultophy(R) Demonstrates Similar Glucose Control with Reduced Risk of Hypoglycaemia and a Superior Heathcare—02 Dec 16

Novo Nordisk today announced new phase 3b trial (DUAL VII) results with Xultophy(R) (IDegLira). Xultophy(R) is a once-daily, single injection fixed combination of a long-acting basal insulin (insulin degludec) and a glucagon-like peptide-1 (GLP-1)

Novo Nordisk Expands Programme to Reach 20,000 Children with Diabetes in Developing Heathcare—14 Nov 16

Today, Novo Nordisk announced a four-year extension of its Changing Diabetes(R) in Children programme which provides access to diabetes care and free insulin to children with type 1 diabetes in developing countries. The expansion sees five new countries

Semaglutide reduced major cardiovascular events by 26% in adults with type 2 diabetes at high Heathcare—16 Sep 16

Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly reduced the risk of the primary composite endpoint of time to first occurrence of either cardiovascular

Victoza(R) lowered the progression of kidney damage in adults with type 2 diabetes at high CV Heathcare—16 Sep 16

Novo Nordisk today announced that the progression of kidney damage was significantly lower with Victoza(R) treatment vs placebo, as measured by urinary albumin creatinine ratio, both added to standard of care in 9,340 adults with type 2 diabetes at high

Semaglutide Demonstrated Superior HbA1c Reduction vs Placebo as Add-on to Basal Insulin Alone or Heathcare—13 Sep 16

Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly improved glycaemic control compared to placebo, as add-on to basal insulin alone or in combination with

Adults with Type 2 Diabetes Treated with Xultophy(R) (IDegLira) were up to 4.5 Times More Likely to Heathcare—13 Sep 16

Novo Nordisk today presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly greater for Xultophy(R) (IDegLira) compared to up-titration with insulin glargine U100 in adults

Novo Nordisk to Present 28 Abstracts at the World Federation of Hemophilia Heathcare—12 Jul 16

Novo Nordisk announced today that data from 28 abstracts will be shared at the upcoming World Federation of Hemophilia World Congress (WFH) in Orlando, Florida, from 24-28 July. The WFH Congress is the largest international meeting for the global

Victoza(R) significantly reduced the risk of major cardiovascular events and death in adults with Heathcare—14 Jun 16

Novo Nordisk today announced that Victoza(R) (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% vs placebo (95% confidence

Novo Nordisk to Present 53 Abstracts at 76th Annual American Diabetes Association Scientific Heathcare—07 Jun 16

Novo Nordisk, a global leader in diabetes care, today announced that data from 53 abstracts including 8 oral presentations will be shared at the upcoming 76th annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, LA, from

Novo Nordisk mark World Haemophilia Day and unveil the 2016 HERO Research Heathcare—18 Apr 16

This material is intended for global medical media only. For journalistic assessment and preparation before publication. Today, on World Haemophilia Day, Novo Nordisk announces that the grant scheme to support and encourage research projects focused on